|
목적 : To investigate the clinical effectiveness of bromfenac sodium hydrate ophthalmic solution for the treatment of cystoid macular edema (CME) after pars plana vitrectomy (PPV).
방법 : A retrospective chart review of 26 patients from July 2016 to Dec 2018 was performed. Seventeen eyes received topical 0.1% bromfenac sodium hydrate ophthalmic solution (nonsteroidal anti-inflammatory [NSAID] drug group), and 9 eyes were treated with intravitreal injection of anti-VEGF agents or steroids (injection group). Best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were measured at baseline and 1, 2, 3, and 6 months after the onset of treatment. Anatomical and functional outcomes were compared between two groups at each visit.
결과 : The incidence of CME was 2.1% (26 of 1,192). There was no significant difference between both groups in baseline characteristics including baseline CMT (p=0.647). Both groups showed no significant difference in the mean change of CMT and BCVA for 6 months (p=0.154, p=0.209, respectively). In the injection group, 1 eye showed elevated in IOP over 30 mmHg. There were no IOP elevations in the NSAID group. Also, there was no significant difference between with cataract surgery group and without cataract surgery group in the mean change of CMT and BCVA for 6 months (p=0.417, p=0.575, respectively).
결론 : Topical bromfenac can be considered along with intravitreal injection of anti-VEGF agents or steroids in order to treat CME after pars plana vitrectomy.
|